他汀类药物与乳腺癌复发风险
Statins and risk of breast cancer recurrence.
作者信息
Sakellakis Minas, Akinosoglou Karolina, Kostaki Anastasia, Spyropoulou Despina, Koutras Angelos
机构信息
Department of Medicine, Division of Oncology, University Hospital, Patras Medical School, Patras.
Department of Statistics, Athens University of Economics and Business, Athens, Greece.
出版信息
Breast Cancer (Dove Med Press). 2016 Nov 4;8:199-205. doi: 10.2147/BCTT.S116694. eCollection 2016.
BACKGROUND
The primary end point of our study was to test whether the concurrent use of a statin is related to a lower risk of recurrence and increased relapse-free survival in patients with early breast cancer.
MATERIALS AND METHODS
We reviewed 610 female patients with stage I, II, or III breast cancer who had been surgically treated and who had subsequently received at least adjuvant chemotherapy in order to prevent recurrence.
RESULTS
Among the 610 patients with breast cancer, 83 (13.6%) were receiving a statin on a chronic basis for other medical purposes. Overall, statin users displayed longer mean relapse-free survival (16.6 vs 10.2 years, =0.028). After data had been adjusted for patient and disease characteristics, statin users maintained a lower risk of recurrence. This favorable outcome in statin users was particularly evident when we included only younger patients in the analysis (20 vs 10 years, =0.006).
CONCLUSION
Statins may be linked to a favorable outcome in early breast cancer patients, especially in younger age-groups.
背景
我们研究的主要终点是检验同时使用他汀类药物是否与早期乳腺癌患者较低的复发风险及延长无复发生存期相关。
材料与方法
我们回顾了610例接受手术治疗且随后接受至少辅助化疗以预防复发的I、II或III期乳腺癌女性患者。
结果
在610例乳腺癌患者中，83例（13.6%）因其他医疗目的长期服用他汀类药物。总体而言，服用他汀类药物者的平均无复发生存期更长（16.6年对10.2年，P = 0.028）。在对患者和疾病特征进行数据调整后，服用他汀类药物者的复发风险更低。当我们仅将年轻患者纳入分析时，服用他汀类药物者的这一良好结果尤为明显（20年对10年，P = 0.006）。
结论
他汀类药物可能与早期乳腺癌患者的良好预后相关，尤其是在年轻人群中。
Zotero 插件